Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Glide Pharma signs up new evaluation partners for Solid Dose Injector

Glide Pharma : 18 June, 2008  (Company News)
Glide Pharma has signed agreements with two more partners to evaluate the Glide SDI - Solid Dose Injector.
The move follows a deal in February 2008 with another leading pharmaceutical company for the delivery of one of its branded peptide products. The Glide SDI is now in feasibility studies with five partners, including two of the top 10 pharmaceutical companies.

The latest studies involve biologics and include a major vaccine company and a listed US biotech company for a home-delivered product.

Glide Pharma’s chief executive officer, Dr Charles Potter, said, “There is particular interest in the Glide SDI system for the injection of biopharmaceuticals and vaccines. The key benefits of the Glide SDI include improved stability of the solid dose, ease-of-use because the system is so simple and there are no reconstitution steps, and safety, as there is no danger of needle-stick injuries. With these benefits, we believe that the Glide SDI is set to make major improvements in the injection of biologics, in a market which is predicted to grow to over $50 billion by 2012”.

In parallel with the partnering successes, Glide Pharma is also working with the UK’s National Institute of Biological Standards and Control (NISBC) that has been conducting studies on vaccine administration using formulations developed by Glide Pharma. Preliminary data suggest enhanced efficacy for vaccines delivered by the Glide SDI compared with those delivered traditionally in a liquid formulation using a needle and syringe. Further trials are being undertaken to confirm these potentially significant findings.

With an increasing number of projects under way, Glide Pharma is currently expanding its facilities at Milton Park, near Oxford, UK, to cope with the increasing demand. “Our work up until this year has focused mainly on development and production of the Glide SDI and our internal drug development programmes, particularly octreotide and fentanyl”, concluded Potter. “2008 has really been the turning point for us in terms of attracting external partners that want to apply the Glide technology to their products. We are expecting to sign further evaluation agreements, as well as convert those that we have to full development relationships, over the coming months.”
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo